Author

Ivana Bravata 1

1 Janssen-Cilag S.p.A.,Milan,Italy

CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL

Silvio Danese, Severine Vermeire, Geert R. D'Haens, Julian Panés, Axel Dignass, Fernando Jose Magro Dias, Maciek Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Fréderic Lavie, Ivana Bravata, Sheldon Sloan, Marco Daperno, Milan Lukas, Alessandro Armuzzi, Mark Lowenberg, Daniel R. Gaya, Laurent Peyrin-Biroulet

CROHN’S DISEASE REAL WORLD THERAPY IN PREVALENT CD-PATIENTS IN GERMANY - THERE IS STILL A GREAT BURDEN OF DISEASE

Beatriz Antolin-Fontes, Evi Zhuleku, Andras Borsi, Riikka Nissinen, Ivana Bravata, Jennifer Norma Barthelmes, Manuela Le Bars, Jennifer Lee, Thomas Wilke, Bernd Bokemeyer, Marco Ghiani

EARLY AND LONG-TERM OUTCOME OF A SINGLE CENTER DATABASE ON ESD FOR COLORECTAL LESIONS WITH SPECIAL EMPHASIS ON LEARNING CURVE IN WESTERN SETTING.

Alberto Murino, Elisa Ferrara, Camilla Ciscato, Silvia Carrara, Cesare Hassan, Ivana Bravatà, Alessandra Loriga, Sandro Sferrazza, Andrea Anderloni, Alessandro Repici

EFFICACY OF TUMOUR NECROSIS FACTOR ANTAGONISTS IN STRICTURING CROHN’S DISEASE: A TERTIARY CENTER REAL-LIFE EXPERIENCE

Mariangela Allocca, Gionata Fiorino, Cristiana Bonifacio, Antonino Spinelli, Ivana Bravatà, Alessandro Repici, Alberto Malesci, Luca Balzarini, Silvio Danese

INTESTINAL ULTRASOUND RESPONSE AND TRANSMURAL HEALING AFTER 48 WEEKS OF TREATMENT WITH USTEKINUMAB IN CROHN'S DISEASE: STARDUST TRIAL SUBSTUDY

Torsten Kucharzik, Rune Wilkens, Giovanni Maconi, Maria-Antonietta D’Agostino, Manuela Le Bars, Marjolein Lahaye, Ivana Bravata, Maciek Nazar, Lioudmila Ni, Elena Ercole, Mariangela Allocca, Nadezda Machkova, Floris de Voogd, Carolina Palmela, Rose Vaughan, Christian Maaser

INTESTINAL ULTRASOUND RESPONSE AND TRANSMURAL REMISSION AFTER 48 WEEKS OF TREATMENT WITH USTEKINUMAB IN CROHN’S DISEASE: STARDUST TRIAL SUBSTUDY RESULTS BY LINE OF TREATMENT AND LOCATION

Rune Wilkens, Maria-Antonietta D'Agostino, Giovanni Maconi, Manuela Le Bars, Marjolein Lahaye, Ivana Bravata, Lioudmila Ni, Elena Ercole, Mariangela Allocca, Nadezda Machkova, Floris A E de Voogd, Carolina Palmela, Rose Vaughan, Christian Maaser, Torsten Kucharzik, Maciej Nazar

LONG TERM ADALIMUMAB EFFICACY IN STEROID-DEPENDENT CROHN’S DISEASE PATIENTS

Ambrogio Orlando, Sara Renna, Filippo Mocciaro, Maria Cappello, Roberto Di Mitri, Ivana Bravatà, Mario Cottone

MOTIVATIONAL INTERVIEWING IN THE OUTPATIENT VISIT: A USEFUL TOOL IN INFLAMMATORY BOWEL DISEASE

Filippo Mocciaro, Roberto Di Mitri, Ivana Bravatà, Salvo Leone

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE–RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY

Silvio Danese, Severine Vermeire, Geert R. D'Haens, Omoniyi J. Adedokun, Julian Panés, Axel Dignass, Fernando Magro, Maciej Nazar, Marjolein Lahaye, Manuela Le Bars, Lioudmila Ni, Daniel R. Gaya, Ivana Bravata, Laurent Peyrin-Biroulet

RISK MARKERS FOR EARLY ATHEROSCLEROSIS IN YOUNG PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Maria Cappello, Anna Licata, Ivana Bravatà, Daniela Dabbene, Alessandra Aiello, Vincenza Calvaruso, Daniele Torres, Antonino Tuttolomondo, Calogero Camma

Item 1 - 10 / 15
1
2